## Clinical Context This patient is in early postmenopause (14 months since last menses) with moderate menopausal symptoms and osteopenia. The question tests understanding of HRT indications, benefits, and risk–benefit analysis in the appropriate window. ## Key Point: **HRT is indicated for moderate-to-severe menopausal symptoms and has dual benefits: symptom relief AND bone protection.** In women within 10 years of menopause onset (or age <60), HRT reduces fracture risk and is appropriate even with osteopenia, provided there are no contraindications [cite:Park 26e Ch 7]. ## High-Yield: **The Women's Health Initiative (WHI) showed increased breast cancer risk with combined estrogen–progestin HRT, but the absolute increase is small (~1 extra case per 1000 women per year) and risk declines after stopping.** Short-term use (5–7 years) in symptomatic women near menopause onset carries a favorable risk–benefit ratio. ## Clinical Pearl: **Osteopenia (T-score −1.0 to −2.5) is NOT a contraindication to HRT; rather, HRT is protective.** Fracture risk reduction occurs through estrogen's direct effect on bone remodeling. This patient's T-score of −1.8 makes her an ideal candidate because HRT will slow bone loss and reduce fracture risk while treating symptoms. ## Mechanism of HRT Benefit in Bone 1. Estrogen suppresses osteoclast activity and prolongs osteoblast lifespan. 2. Reduces bone turnover and increases BMD by 2–3% annually in the first 5 years. 3. Fracture risk reduction is independent of BMD change (also involves improved bone quality). ## Timing Window **HRT is most effective and safest when started within 10 years of final menstrual period or before age 60.** This patient (age 52, 14 months postmenopausal) is in the ideal window.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.